Aadi Bioscience, Inc.
NASDAQ:AADI
Overview | Financials
Company Name | Aadi Bioscience, Inc. |
Symbol | AADI |
Currency | USD |
Price | 1.99 |
Market Cap | 48,983,452 |
Dividend Yield | 0% |
52-week-range | 1.21 - 5.7 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. David J. Lennon Ph.D. |
Website | https://aadibio.com |
An error occurred while fetching data.
About Aadi Bioscience, Inc.
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD